Can a cancer drug spray stop debilitating nosebleeds?
NCT ID NCT02157987
First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time
Summary
This trial tests whether a nasal spray containing bevacizumab, a drug typically used for cancer, can reduce frequent nosebleeds in people with hereditary hemorrhagic telangiectasia (HHT). The study enrolls 20 adults who have at least 10 nosebleeds per month. The goal is to see if the spray can cut the number of monthly nosebleeds by at least half.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- bevacizumab nasal spray
- What this could lead to
- If it works, this could offer a simple, non-surgical way to control frequent nosebleeds in people with HHT, improving quality of life.
- What could go wrong
- This is an early-phase trial with only 20 participants, so results may not apply broadly. The spray's effectiveness and safety are still unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TELANGIECTASIA, HEREDITARY HEMORRHAGIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de Caen
Caen, 14033, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.